The Src inhibitor peptide TAT-Cx43_266-283 improves survival in an intracranial murine model of lung cancer brain metastasis.

ABSTRACT:

Background

TAT-Cx43_266-283 is a novel Src inhibitor, which has shown noteworthy antitumor effects in preclinical models of glioblastoma. Because Src plays a pivotal role in several tumor types, including lung cancer brain metastasis derived from non-small cell lung cancer (NSCLC) cells, we investigated the effect of TAT-Cx43_266-283 in NSCLC-derived brain metastasis, a disease of unmet clinical need.

Methods

The effect of TAT-Cx43_266-283 was studied in Lewis Lung Carcinoma (LLC), LSZ4, A549, and H441 NSCLC cells. The non-adherent stem-like LLC cells (LLC-CSCs) were intracranially implanted in immunocompetent mice to study the effect of TAT-Cx43_266-283  in vivo. Phosphoproteomic analysis was employed to identify signaling path

SUBMITTER: Cervero-Garcia P 

PROVIDER: S-EPMC12932952 | biostudies-literature | 2026 Jan-Dec

REPOSITORIES: biostudies-literature